Analyst Reco. Karyopharm Therapeutics Inc.

Equities

KPTI

US48576U1060

Real-time Estimate Cboe BZX Other stock markets 15:06:09 29/04/2024 BST			5-day change	1st Jan Change
1.125 ^USD	+6.13%		-1.77%	+28.32%

04-24	Karyopharm Therapeutics Inc. Announces Presentations in Endometrial Cancer and Myelofibrosis At the 2024 American Society of Clinical Oncology Annual Meeting	CI
03-13	Transcript : Karyopharm Therapeutics Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:00 AM

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RBC Cuts Price Target on Karyopharm Therapeutics to $3 From $4, Keeps Outperform Rating	11-03	MT
Wedbush Trims Karyopharm Therapeutics' PT to $3 From $4, Sees Limited Upside Near Term; Maintains Neutral Rating	11-03	MT
Morgan Stanley Adjusts Price Target on Karyopharm Therapeutics to $4 From $5, Maintains Equal-Weight Rating	07/08/23	MT
RBC Cuts Price Target on Karyopharm Therapeutics to $4 From $5, Maintains Outperform Rating	03/08/23	MT
Wedbush Cuts Karyopharm Therapeutics' PT to $4 From $7, Lowers Peak Sales Estimate for Selinexor; Keeps Neutral Rating	26/07/23	MT
Baird Adjusts Karyopharm Therapeutics' Price Target to $10 From $14, Keeps Outperform Rating	05/05/23	MT
HC Wainwright Adjusts Karyopharm Therapeutics Price Target to $10 From $16, Maintains Buy Rating	05/05/23	MT
RBC Cuts Price Target on Karyopharm Therapeutics to $5 From $6, Maintains Outperform Rating	05/05/23	MT
Wedbush Lifts Karyopharm Therapeutics' Price Target to $7 From $6 After Adding in Valuation for Selinexor in 1L Myelofibrosis, Keeps Neutral Rating	19/04/23	MT
RBC Cuts Price Target on Karyopharm Therapeutics to $6 From $7, Maintains Outperform Rating	16/02/23	MT
Piper Sandler Starts Karyopharm Therapeutics at Overweight With $8 Price Target	19/01/23	MT
RBC Cuts Price Target on Karyopharm Therapeutics to $7 From $9, Maintains Outperform Rating	13/01/23	MT
HC Wainwright Adjusts Price Target on Karyopharm Therapeutics to $16 From $18, Maintains Buy Rating	10/01/23	MT
SVB Securities Adjusts Price Target on Karyopharm Therapeutics to $5 From $6, Maintains Market Perform Rating	10/01/23	MT
Wedbush Trims Karyopharm Therapeutics' Price Target to $6 From $7, Keeps Neutral Rating	10/01/23	MT
SVB Securities Adjusts Price Target on Karyopharm Therapeutics to $6 From $5, Maintains Market Perform Rating	04/11/22	MT
RBC Upgrades Karyopharm Therapeutics to Outperform From Sector Perform, Boosts Price Target to $10 From $7, Cites 'Improving Uptake' for Xpovio, 'Promising' Mylofibrosis Data	04/11/22	MT
Morgan Stanley Adjusts Price Target on Karyopharm Therapeutics to $7 From $10, Maintains Equalweight Rating	09/09/22	MT
Morgan Stanley Cuts Price Target on Karyopharm Therapeutics to $7 From $10, Maintains Equalweight Rating	09/09/22	MT
Baird Lowers Karyopharm Therapeutics Price Target to $14 From $17, Maintains Outperform Rating	05/08/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Karyopharm Therapeutics Inc.

Equities

KPTI

US48576U1060

Analyst Reco.

Filters